Atypical pneumonias

Respiratory Syncytial Virus (RSV) Prevention Clinical Landscape Report 2021: Synagis is Currently the Only Marketed Preventive Agent in the RSV Space and Generates Blockbuster Sales - ResearchAndMarkets.com

Retrieved on:

Mercredi, juillet 21, 2021

Health, General Health, Medical specialties, Vaccination, Atypical pneumonias, Clinical medicine, Virology, Respiratory syncytial virus, Syncytial virus, Medicine, Palivizumab, RSV, Vaccine

The "Disease Analysis: Respiratory Syncytial Virus (RSV) Prevention" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Disease Analysis: Respiratory Syncytial Virus (RSV) Prevention" report has been added to ResearchAndMarkets.com's offering.
Synagis is currently the only marketed preventive agent in the RSV space and generates blockbuster sales.
Sanofi is intending to price nirsevimab comparably to other pediatric vaccines to facilitate reimbursement for universal use as an at-birth dose.
Pediatric vaccines in development include GlaxoSmithKline's GSK3389245A, Johnson & Johnson's JNJ-64400141, Sanofi's portfolio of live-attenuated vaccines (LAVs), and Meissa Vaccines' MV-012-968.

ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose

Retrieved on:

Mardi, juillet 13, 2021

Coronaviridae, Respiratory diseases, Zoonoses, Sarbecovirus, Atypical pneumonias, Bat virome, COVID-19, Occupational safety and health, TLR2, Severe acute respiratory syndrome, COVID-19 vaccine

By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.

Key Points:

By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.
The Phase I study is a randomized, double-blind and placebo-controlled, single and multiple ascending dose study.
The easy-to-use nasal spray could be helpful in protecting at-risk populations, such as the elderly or patients with chronic respiratory diseases.
Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

Retrieved on:

Mercredi, juin 30, 2021

Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the first seronegative participants have received MV-012-968, Meissas intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children.

Key Points:

Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the first seronegative participants have received MV-012-968, Meissas intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children.
Meissa is developing MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and at-risk, older adults from respiratory syncytial virus (RSV).
We believe that our intranasal live attenuated RSV vaccine candidate, developed on Meissas AttenuBlockTM vaccine platform, offers the potential to finally immunize against RSV, which has evaded other vaccine technologies for more than 60 years, said Martin Moore, Ph.D., CEO and cofounder of Meissa Vaccines.
Meissa is advancing live attenuated vaccine candidates against respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).

Therma Bright to Test AcuVid(TM) on the Highly Contagious COVID-19 Delta Variant, Company Completes Brazilian Clinical Study for Final FDA EUA Submission

Retrieved on:

Jeudi, juin 24, 2021

Respiratory diseases, Animal diseases, Medical specialties, Occupational safety and health, Atypical pneumonias, COVID-19, Public health, Zoonoses, Severe acute respiratory syndrome

Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall.

Key Points:

Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall.
"We are excited that our Brazilian clinical study has now met the minimum FDA-EUA requirements for our submission to secure serial testing approval," expressed Rob Fia, Therma Bright's CEO.
Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs.

ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19 VACCINES EFFECTIVE AT PREVENTING AND MODERATING EFFECTS OF INFECTIONS

Retrieved on:

Mardi, juin 8, 2021

Medical specialties, Health, Clinical medicine, Occupational safety and health, Atypical pneumonias, COVID-19, Public health, Zoonoses, Severe acute respiratory syndrome, Breakthrough infection, MedRxiv

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.

Key Points:

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.
The study was released in preprint via medRXiv.
Such studies increase the publics knowledge and understanding of COVID-19, adds Project Director Danielle Hunt, an Abt vice president and senior epidemiologist.
Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people's lives.

ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19 VACCINES EFFECTIVE AT PREVENTING AND MODERATING EFFECTS OF INFECTIONS

Retrieved on:

Mardi, juin 8, 2021

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.

Key Points:

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.
The study was released in preprint via medRXiv.
Such studies increase the publics knowledge and understanding of COVID-19, adds Project Director Danielle Hunt, an Abt vice president and senior epidemiologist.
Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people's lives.

AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen

Retrieved on:

Jeudi, mai 27, 2021

Atypical pneumonias, Medical specialties, Sarbecovirus, Infectious diseases, Health, Rintatolimod, Severe acute respiratory syndrome, COVID-19 pandemic

AIM entered into the agreement on April 1, 2020, to study the utilization of an innovative Smoore inhalation delivery device and Ampligen as a potential treatment approach for the SARS-CoV-2 pandemic.

Key Points:

AIM entered into the agreement on April 1, 2020, to study the utilization of an innovative Smoore inhalation delivery device and Ampligen as a potential treatment approach for the SARS-CoV-2 pandemic.
On parallel paths, over the past year, Smoore has focused on the development of a personal inhalation device designed to administer Ampligen, given temperature parameters of dsRNA.
"We are in the process of planning a Phase 1/2 inhalation clinical study on a parallel track with Smoores device development testing.
The agreement with Smoore is to preliminarily study the utilization of an innovative Smoore inhalation delivery device and Ampligen as a potential treatment approach for the SARS-CoV-2 pandemic.

Preliminary results suggest nearly 6% of Montreal children tested from October to April had antibodies to SARS-CoV-2

Retrieved on:

Mardi, mai 18, 2021

Sarbecovirus, Medical specialties, Respiratory diseases, Health sciences, Occupational safety and health, Atypical pneumonias, Epidemiology, Serology, Seroprevalence, Severe acute respiratory syndrome coronavirus, COVID-19, Severe acute respiratory syndrome

As an overall average, 5.8% of participating children were found to have antibodies to SARS-CoV-2, the virus that causes COVID-19.

Key Points:

As an overall average, 5.8% of participating children were found to have antibodies to SARS-CoV-2, the virus that causes COVID-19.
By April 2021, in the third wave, 8.9% of the students tested had antibodies.
\xe2\x80\x9cThe results also suggest that seroprevalence is higher in neighbourhoods with lower socio-economic indexes and at a greater percentage for racialized residents.
The blood samples were taken from 354 children in daycare, 725 children in elementary schools, and 553 students in high schools.

SAVE LIVES: Clean Your Hands – ECDC supports World Hand Hygiene Day 2021

Retrieved on:

Vendredi, mai 7, 2021

Health, Medical specialties, Occupational safety and health, Atypical pneumonias, COVID-19 pandemic, Hygiene, Hand washing, COVID-19, Severe acute respiratory syndrome, Sally Bloomfield, Infection prevention and control

However, a large percentage of these infections are preventable by improving hand hygiene practices.

Key Points:

However, a large percentage of these infections are preventable by improving hand hygiene practices.
In the context of the COVID-19 pandemic, hand hygiene also is one of the most effective ways of reducing the spread of SARS-CoV-2.
With this years slogan Seconds save lives clean your hands!, the World Health Organization calls on healthcare workers to achieve effective hand hygiene at the point of care.
To be effective, hand hygiene should be performed: at 5 specific moments (i.e.

COVID-19 has caused 6.9 million deaths globally, more than double what official reports show

Retrieved on:

Jeudi, mai 6, 2021

Articles, Health, Sarbecovirus, Occupational safety and health, Atypical pneumonias, Zoonoses, Biological hazards, Institute for Health Metrics and Evaluation, COVID-19, Pandemic, Severe acute respiratory syndrome, COVID-19 pandemic

b'Many deaths from COVID-19 go unreported because countries only report deaths that occur in hospitals or in patients with a confirmed infection.

Key Points:

b'Many deaths from COVID-19 go unreported because countries only report deaths that occur in hospitals or in patients with a confirmed infection.
However, some countries with relatively smaller epidemics saw a large increase in the death rate when accounting for unreported deaths.
Moving forward, IHME\'s COVID-19 modeling, which forecasts the potential course of the pandemic over the next several months, will be based on these estimates of total COVID-19 deaths.
The resulting adjusted estimates include only deaths directly due to the SARS-CoV-2 virus, which causes COVID-19.